home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/50a8575a-f9cf-42c0-abae-641eeca9c86b_Market_Acces_Phase2_infographic.pdf
infographic
SHARESHARESHARE
MULTIPLE MYELOMA PRICING, REIMBURSEMENT, AND ACCESS
Payers have become increasingly aware of the potential cost burden of multiple myeloma treatment over the past five years, due to several factors, The approvals of several high-cost biologics in increasingly early treatment lines, Increased patient life expectancies resulting in extended treatment durations, The surge in demand for high-cost combination regimens DOWNLOAD